Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Anemia, Aplastic

• The Optimization of Conditioning Regimen for HLA Matched HSCT in SAA
• Efficacy and Safety of CsA+AVA in the Treatment of NSAA in the Elderly
• JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure
• Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients With Aplastic Anemia
• Safety and Effectiveness of Trappa Ethanolamine Tablets Combined With Ciclosporin in the Treatment of Primary Treatment of Non-severe Aplastic Anemia
• Clinical Study of UCB Combined With UC-MSCs in the Treatment of Bone Marrow Failure Disorders
• A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia
• Avatrombopag Combined With IST as First-line Treatment for SAA
• Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia
• A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)
• Efficacy and Safety of Avatrombopag Combined With IST for the Treatment of HAAA and SAA With Abnormal Liver Function
• A Randomized,Open-label Dose-discovery Study of PEG-rhG-CSF and rhG-CSF Used for Aplastic Anemia Granulocyte Deficiency
• The Safety and Efficacy Study of Avatrombopag Switch in TPO-RA Refractory AA
• GVHD Prophylaxis by Addition of CD20 Monoclonal Antibody to the Conditioning Regimen in SAA With Treatment of Allo-HSCT
• Efficacy and Safety of CSA and Avatrombopag for the Treatment of SAA in the Elderly
• Efficacy and Safety in Transfusion Independent Non-severe Aplastic Anemia
• Efficacy of Romiplostim in Treatment of Severe Aplastic Anemia in Non-Asian Adults Previously Untreated With or Refractory to Immunosuppressive Therapy
• A Bioequivalence Study of Hetrombopag in Healthy Subjects
• A Trial of Hetrombopag in Healthy and Hepatic Impairment Subjects
• A Trial of Hetrombopag in Healthy Subjects
• Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant
• Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia
• Extension Study of Hetrombopag in Severe Aplastic Anemia
• Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic Anemia
• Avatrombopag Usage in NSAA
• Haploidentical HCT for Severe Aplastic Anemia
• TPO-Mimetic Use in Children for Hemotopoietic Failure
• Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
• REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy
• Efficacy and Safety of Eltrombopag + Tacrolimus/Cyclosporin A in Chinese Refractory or Relapsed Aplastic Anemia Patients
• Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia
• Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)
• AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
• Study of AMG531 (Romiplostim) in Patients With Aplastic Anemia
• Study to Assess the Safety and Efficacy of Eltrombopag in Chinese Refractory or Relapsed Severe Aplastic Anemia (SAA) Subjects.
• Study of AMG531(Romiplostim) in Patients With Aplastic Anemia
• A Novel TBI Free Conditioning Protocol for Haploidentical Transplant in Acquired Aplastic Anemia:
• Combination of Thrombopoietin Mimetic and Immunosuppressive Therapy in Aplastic Anaemia
• Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia
• Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAA
• Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
• Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
• T Cell Receptor α/β TCD HCT in Patients With Fanconi Anemia
• A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia （SAA） Patient
• T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia
• Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis
• Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
• Eltrombopag+hATG+CsA vs. hATG+CsA in Children With Severe AA
• Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
• Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients
• Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
• Peripheral Blood Allogenic Stem Cell Transplantation Using Non-anti Thymocyte Globulin Regimens in Severe Aplastic Anemia Patients
• Eltrombopag in Children With Idiopathic Aplastic Anemia
• Clinical Study of Non Severe Aplastic Anemia Treated With Cyclosporine, Androgen and Levamisole
• Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
• A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia
• Umbilical Cord Blood Transplantation From Unrelated Donors
• Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia
• Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy
• Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
• Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)
• King's Invasive Aspergillosis Study II
• Efficacy and Safety of Thrombopoietin In Patients With Severe and Very Severe Aplastic Anemia
• Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia
• ATG Combined With Cyclophosphamide And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia
• NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia
• Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia
• Efficacy and Safety of Eltrombopag + CSA in Patients With Moderate Aplastic Anemia (EMAA)
• The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia
• Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
• Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome
• Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome
• Safety and Efficacy of Patient's Own AD-MSC and AD-HSC Transplantation in Patients With Severe Aplastic Anemia
• Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects
• Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia
• A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia
• Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia
• A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia
• Effectiveness and Safety of MMSCs for Enhancing Hematopoietic Recovery and Prophylaxis of Neutropenic Enterocolitis
• hATG+CsA vs hATG+CsA+Eltrombopag for SAA
• A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia
• Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant
• Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis
• Nandrolone Decanoate in the Treatment of Telomeropathies
• Comparison of Two Different Doses of Rabbit ATG-Fresenius With Cyclosporin in the Treatment of Acquired Aplastic Anaemia
• Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia
• Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia
• Bone Marrow Transplant With Abatacept for Non-Malignant Diseases
• Extended Dosing With Eltrombopag for Severe Aplastic Anemia
• Russian Clinical Trial of Mesenchymal Cells in Patients With Septic Shock and Severe Neutropenia
• Randomised Study Comparing Different Dosages of Rabbit ATG in Patients With SAA
• DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
• Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients
• Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
• Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)
• Haploidentical Stem Cell Transplantation for Children With Acquired Severe Aplastic Anemia
• Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia
• Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes
• Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
• Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria
• Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
• Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia
• Human Placental-Derived Stem Cell Transplantation
• Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia
• Prospective Phase II Study of Rabbit Antithymocyte Globulin (ATG, Thymoglobuline®, Genzyme) With Ciclosporin for Patients With Acquired Aplastic Anaemia
• Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
• Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
• Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
• Pharmacokinetic Study of Fludarabine in Pediatric Hematopoietic Stem Cell Transplantation
• Danazol for Genetic Bone Marrow and Lung Disorders
• Alemtuzumab and Rituximab in Aplastic Anemia
• A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
• Pilot Phase I/II Study of Amino Acid Leucine in Treatment of Patients With Transfusion-Dependent Diamond Blackfan Anemia
• A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
• Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor
• Trial of Two Central Venous Catheter (CVC) Flushing Schemes in Pediatric Hematology and Oncology Patients
• Eltrombopag for Moderate Aplastic Anemia
• Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation
• Alefacept in Patients With Relapsed/Refractory Aplastic Anemia
• Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia
• Traditional Chinese Medicine in the Supportive Management of Anaemic and Cytopenic (Leukopenia, Thrombocytopenia) Haematological Disorders
• Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
• Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia
• Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)
• A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia
• Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies
• Randomized Study In Severe Aplastic Anemia Patients Receiving Atg, Cyclosporin A, With Or Without G-CSF (SAA-G-CSF)
• Comparison of Cy-Atg vs Flu-Atg for the Conditioning Therapy in Allo-HCT for Adult Aplastic Anemia
• Reduced-Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia
• Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Aplastic Anemia
• Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine
• Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States
• Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone
• Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine
• Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
• Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA Treatment
• A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients
• Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure
• Reduced Toxicity Fludarabine (Flu) + Cyclophosphamide (CPM) + Rabbit Antithymocyte Globulin (rATG) Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia (SAA)
• Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders
• Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome
• Comparison of Cy-Atg Vs Cy-Flu-Atg for the Conditioning Therapy in Allo-HCT
• Flu+CPM+rATG Conditioning Regimes for Unrelated Bone Marrow Transplantation (UBMT)(or Mobilized Peripheral Blood)in Severe Aplastic Anemia (SAA)
• T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
• Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders
• Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia
• Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia
• Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia
• Treatment of Menorrhagia in Women With Thrombocytopenia Using Platelets or Platelets and Hormones
• Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders
• Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT
• Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
• Rabbit Antithymocyte Globulin (Thymoglobuline) With Ciclosporin for Patients With Acquired Aplastic Anaemia
• Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA
• Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia
• Safety and Efficacy Study of Ex Vivo Immunotherapy for Treatment of Aplastic Anemia
• Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor
• Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
• Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Nonca
• Cyclophosphamide, Antithymocyte Globulin, and Total-Body Irradiation in Treating Patients With Severe Aplastic Anemia Undergoing Umbilical Cord Blood Transplant
• A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies
• Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant
• Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)
• Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia
• Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia
• Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia
• Oxandrolone for the Treatment of Bone Marrow Aplasia in Fanconi Anemia
• Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia
• Alemtuzumab to Treat Severe Aplastic Anemia
• Purified CD34+ Hematopoietic Stem Cell Transplantation From Alternate Donors for Patients With Severe Aplastic Anemia
• Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndr
• SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes
• Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes
• Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia
• XK469R in Treating Patients With Refractory Hematologic Cancer
• Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
• CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase
• Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia
• Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias
• Improving Immunosuppressive Treatment for Patients With Severe Aplastic Anemia
• Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
• NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
• Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia
• Study of Allogeneic Bone Marrow and T-Cell Depleted, CD34+ Peripheral Blood Stem Cell Transplantation in Patients With Aplastic Anemia
• Thalidomide in Treating Patients With Myelodysplastic Syndrome
• Stem Cell Mobilization Potential in Patients With Aplastic Anemia in Remission
• Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk My
• BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia
• Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy
• Mycophenolate Mofetil and Cyclosporine to Treat Relapsing Aplastic Anemia
• Tipifarnib in Treating Patients With Myelodysplastic Syndromes
• PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome
• Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
• Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia
• Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
• Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia
• Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes
• Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
• Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
• Combination Therapy of Severe Aplastic Anemia
• A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure
• Comparing Therapies for the Treatment of Severe Aplastic Anemia
• Stem Cell Factor Medication for Aplastic Anemia
• Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders